Amarin Corporation plc (NASDAQ:AMRN) Files An 8-K Results of Operations and Financial Condition

0

Amarin Corporation plc (NASDAQ:AMRN) Files An 8-K Results of Operations and Financial Condition

Item2.02. Results of Operations and Financial Condition.

On January5, 2017, Amarin Corporation plc, or the Company, issued
a press release providing preliminary unaudited fourth quarter
and annual 2016 financial guidance and its financial outlook for
2017. A copy of the Companys press release is furnished herewith
as Exhibit 99.1.

The information set forth under Item2.02 and in Exhibit 99.1
is intended to be furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits


ExhibitNo.


Description

99.1 Press Release, dated January5, 2017


** *


About Amarin Corporation plc (NASDAQ:AMRN)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Company markets Vascepa in the United States.

Amarin Corporation plc (NASDAQ:AMRN) Recent Trading Information

Amarin Corporation plc (NASDAQ:AMRN) closed its last trading session down -0.06 at 3.00 with 1,754,297 shares trading hands.